Junhao Zhou

Junhao Zhou

Auto-generated profile, based on publicly available information

Junhao Zhou

The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Oncology Reports
Verified
Journal Article
Open access
PDF file
PHPengkai Han
Pengkai Han
JZJunhao Zhou
Junhao Zhou
JXJianhua Xiang
Jianhua Xiang
QLQiping Liu
Qiping Liu
KSKai Sun
Kai Sun
Lung cancer is the most common type of cancer and the leading cause of cancer‑associated death worldwide. Despite the availability of various treatments such as surgery, chemoradiotherapy, targeted drugs and immunotherapy, treatment is expensive and the prognosis remains poor. At present, lung cancer drugs and treatment programs remain in a state of continuous exploration and research to improve the prognosis, and to reduce the pain and economic burden for the patients. Type 2 diabetes is a common chronic disease in middle‑aged and elderly patients, leading to significantly increased complications of cardiovascular and cerebrovascular diseases. Epidemiology shows that type 2 diabetes also increases the incidence of malignant tumors, including lung, liver, colorectal and pancreatic cancer. Metformin is a biguanide, widely used as a first‑line oral drug in treating type 2 diabetes. Metformin has a hypoglycemic effect and a biological antitumor impact, reducing the incidence of various tumors, including lung cancer, and improving the prognosis of patients with tumors. The anti‑lung cancer effect of metformin involves a variety of mechanisms that can improve the therapeutic effect and prognosis of lung cancer, as a single drug or in combination with other therapies. The present study aims to review the associated literature and the therapeutic effects of metformin on lung cancer.

18 August 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
PHPengkai Han
Pengkai Han
YFYunxiu Fan
Yunxiu Fan
QLQiping Liu
Qiping Liu
JZJunhao Zhou
Junhao Zhou
Background. Lung adenocarcinoma is the most common lung cancer subtype and accounts for the highest proportion of cancer-related deaths. The tumor microenvironment influences prognostic outcomes in lung adenocarcinoma (LUAD). Materials and Methods. We used the ESTIMATE algorithm (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) to investigate the role of microenvironment-related genes and stromal cells in lung adenocarcinoma prognosis. This analysis was done on lung adenocarcinoma cases from The Cancer Genome Atlas (TCGA). The cases were divided into high and low groups on the basis of immune and stromal scores, respectively. Results. There were close correlations between immune scores with prognosis and disease stage. There were 367 differentially expressed genes. Combining the Gene Expression Omnibus (GEO) database, we found 14 prognosis-related genes. Results. Based on the enrichment levels of the immune cell types, we clustered LUAD into Immunity_H and Immunity_L subtypes. Most of these genes were upregulated in Immunity_H subtype. Finally, using the Human Protein Atlas (HPA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases, most of the proteins corresponding to prognostic genes were verified to be differentially expressed between the tumor and normal groups. Conclusions. The key genes identified in this study are involved in molecular mechanisms of LUAD.

5 September 2026
Verified
Conference Paper
Closed access
JZJunhao Zhou
Junhao Zhou
YZYuan Zhan
Yuan Zhan
LXLi Xu
Li Xu
SGShuliang Guo
Shuliang Guo
INTRODUCTION: COPD is a heterogeneous disease typically characterized by chronic airway inflammation, with emerging evidence highlighting the driving role of cellular senescence-related lung aging. By methylating mRNAs that encode aging-related factors, NSUN2 is emerging as an important regulator of cellular senescence and inflammation. OBJECTIVES: To investigate the role and mechanism of NSUN2 in COPD pathogenesis. METHODS: Expressions of NSUN2 were evaluated by bioinformatic analysis combined with detections in clinical specimens. The effects of NSUN2 on inflammation and senescence were investigated via constructing cell model with siRNA transfection or overexpression lentivirus infection and animal model with NSUN2 overexpression adenovirus via intratracheal administration. MeRIP-seq was performed to probe the influence of RNA methylation in NUSN2 expression in COPD. RESULTS: NSUN2 expression was significantly decreased in COPD patients and strongly associated with lung function. NSUN2 downregulation was confirmed in mice exposed to cigarette smoke (CS) for 3 months, 6 months and 9 months with a linear trend, and bronchial epithelial cells treated by CS extract as well. Mechanically, NSUN2-inhibited inflammation and cellular senescence directly mediated by AKAP12 in a m5C methylation independent manner. Furthermore, NSUN2 overexpression remarkably alleviated airway inflammation and senescence of lungs in CS-exposed mice, as well as improved emphysema and lung function. CONCLUSION: Our findings have shed light on the impact of NSUN2 in the pathogenesis of COPD, thereby offering a promising target for intervention in clinical settings.